Mixed Adenocarcinoma and
Neuroendocrine Carcinoma Arising
in the Urachus

Munichor, Mariana; Szvalb, Sergio; Cohen, Hector; Bitterman, Wilhelm

doi:10.1159/000475079

Cited by 26 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Endometrial adenocarcinoma can also mimic a bladder primary, but can be differentiated in more than 90% of cases by vimentin positivity. 25 Unusual secondary tumours of the bladder must be distinguished from rare primary tumours, 32 including small cell carcinoma, [33][34][35] malignant melanoma, [36][37][38] osteosarcoma 39 and clear cell carcinoma. 40,41 In practice, knowledge of a history of tumour elsewhere, and comparison with the original histology will establish the secondary nature of a bladder tumour in many cases, particularly as tumours that have spread to the bladder tend to be at an advanced stage.…”

Section: Discussionmentioning

confidence: 99%

Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases

2000

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases

2000

View full text Add to dashboard Cite

show abstract

“…14,15 Other histological types of tumors are also seen involving the urachus, including sarcomas (leiomyosarcoma, rhabdomyosarcoma, and malignant fibrous histiocytoma [MFH]), small cell carcinomas, transitional cell cancer, and mixed neoplasias. 15 In the current article, these tumors represent 10% of our cases.…”

Section: 12mentioning

confidence: 99%

Predictors of survival from urachal cancer

Molina

Quevedo

Furth

et al. 2007

Cancer

148

164

View full text Add to dashboard Cite

Objective Antineutrophil cytoplasmic antibody–associated vasculitis (AAV) is characterized by necrotizing vessel wall inflammation, paralleled by the detachment of endothelial cells. The repair of such endothelial defects is crucial for the maintenance of regular structure and function of the injured vessels. Bone marrow–derived endothelial progenitor cells (EPCs) are thought to play a pivotal role in the regeneration of damaged endothelium. The aim of this study was to investigate whether EPCs are involved in vascular repair in AAV. Methods We assessed disease activity, CD34+ hematopoietic progenitor cells (HPCs) using flow cytometry, EPCs using an in vitro assay, and circulating endothelial cells (CECs) by immunomagnetic isolation from the peripheral blood of 31 patients with active AAV at 1, 3, and 6 months after the initiation of immunosuppressive therapy. Results In patients with untreated active disease, HPC and EPC numbers were comparable with those in healthy control subjects (n = 64). With the induction of remission, the number of HPCs and EPCs increased significantly, from a median of 1.5 cells/μl (range 0.0–7.0) to a median of 3.2 cells/μl (range 0.76–9.2) (P < 0.001) and from a median of 261 cells/high‐power field (range 171–643) to a median of 470 cells/high‐power field (range 168–996) (P < 0.021), respectively. In contrast, the initially elevated number of CECs decreased significantly (P < 0.001). We observed no correlation between the number of HPCs or EPCs and the leukocyte count, the thrombocyte count, or kidney function. Conclusion In patients with AAV, the numbers of circulating CD34+ HPCs and EPCs increased significantly after the institution of immunosuppressive therapy and disease remission. This finding points to a role of circulating CD34+ HPCs and EPCs in endothelial repair in vasculitis. Targeted stimulation of these cells might represent a new possibility of improving vascular healing in AAV.

show abstract

“…Hue and Jacquin had presented urachal tumors for the first time in the 19th century. They consist of less than 1% of all bladder cancers and about 30% of primary adenocarcinomas (7).…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Urachal Adenocarcinoma: Long Term Follow Up

et al. 2018

View full text Add to dashboard Cite

Introduction:Urachal adenocarcinoma is an invasive and rare bladder carcinoma that usually presents at advances stages with poor prognosis. The symptoms often include abdominal pain and hematuria. The standard treatment method is surgical excision of the tumor and sometimes, in advanced cases, chemotherapy is needed, too. Case Presentation: We present a 35-year-old male patient, who referred with acute onset of painless macroscopic hematuria. Pelvic CT scan showed a large mass on the bladder dome, extending to the umblicus. Biopsy of the mass confirmed that the pathologic diagnosis was urachal adenocarcinoma. The patient was then treated surgically with partial cystectomy approach. Conclusions: Despite microscopic involvement of pelvic lymph nodes, adjuvant therapy was not intended. There were no local recurrence or distant metastasis in long term close follow up.

show abstract

Mixed Adenocarcinoma and Neuroendocrine Carcinoma Arising in the Urachus

Cited by 26 publications

References 13 publications

Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases

Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases

Predictors of survival from urachal cancer

A Rare Case of Urachal Adenocarcinoma: Long Term Follow Up

Contact Info

Product

Resources

About